Non-invasive fluorescence measurements in tissues.

<p>Non-invasive fluorescence measurements in tissues.</p

Histological characterization of human A431 subcutaneous tumors in nude mice.

<p>Subcutaneous tumor (T) (x4) developed at D7 after inoculation of A431 (histological section 5μm in Hematoxylmin Eosin Safran): Peritumoral edema (O), Dermis (D) B. Keratinized cancer cells (x40).</p

Intratissular PpIX concentrations as a function of tumor depth after m-ALA topical application.

<p>Intratissular PpIX concentrations as a function of tumor depth after m-ALA topical application.</p

PpIX accumulation at different depths of the tumor after 3h and 6h of topical m-ALA application.

<p>(A) m-ALA induced PpIX formation throughout the depth of tumor, assessed every 500 μm up to 2 mm. PpIX accumulation in exposed skin and unexposed adjacent skin is also presented for comparison. Insert to the panel A provides PpIX concentration decay in most superficial tumor region (up to 1.5 mm), measured every 250 μm. (B) PpIX concentration ratio tumor/ adjacent skin at different depth of the tumor after 3h or 6h m-ALA topical application. (ExpS: Exposed skin; UnexpS: Unexposed skin).</p

Fluorescence ratio as a function of tumor depth.

<p>Fluorescence ratio as a function of tumor depth.</p

Samples characteristics.

<p>Samples characteristics.</p

Workflows for the different assays used for <i>BRAF</i> mutation analysis.

<p>Workflows for the different assays used for <i>BRAF</i> mutation analysis.</p

Samples with discrepancies.

<p>Samples with discrepancies.</p

Mutation results per assay.

<p>Mutation results per assay.</p

Performance statistics of the BRAF detection with the four validated assays compared to NGS.

<p>Performance statistics of the BRAF detection with the four validated assays compared to NGS.</p